教育背景
1986年毕业于第四军医大学军医系，获学士学位；1989年在第四军医大学获硕士学位；1994年在军事医学科学院获博士学位。
工作经历
1996年赴美国Thomas Jefferson大学和Sloan-Kettering肿瘤中心，及其后在中国医学科学院肿瘤研究所做博士后研究。2001年起，任药物研究所课题组长，副研究员，研究员。

长期从事分子药理学和肿瘤药理学研究工作，关注以基因转录调控为基础的肿瘤学和药理学研究，主要围绕表基因组学靶点进行抗肿瘤药物研究。通过建立组蛋白去乙酰酶抑制剂筛选模型，筛选了大量的化合物，发现了一些活性化合物和候选抗肿瘤药物，并进行了相关的抗肿瘤作用机制的研究工作。也在其它药物靶点及蛋白质相互作用的研究上开展了初步的工作。我们今后的研究方向，将主要围绕新靶点作用的药物，进行药理学机制、相关药理学研究和候选药物的临床前研究工作，并在生物技术药物领域，开展一些工作。

1. NCTR25 fusion facilitates the formation of TRAIL polymers that selectively activate TRAIL receptors with higher potency and efficacy than TRAIL. Yan Wang, Qiong Lei, Cangjie Shen, Nan Wang. Cancer Chemotherapy and Pharmacology. 2021.
2. Dimerization/oligomerization of the extracellular domain of the GLP-1 receptor and the negative cooperativity in its ligand binding revealed by the improved NanoBiT. Xiaohan Song, Yi Yu, Cangjie Shen, Yubo Wang, Nan Wang. FASEB Journal. 2020.
3. A New Metal Affinity NCTR 25 Tag as a Better Alternative to the His-tag for the Expression of Recombinant Fused Proteins. Weitong Pan, Yan Wang, Nan Wang. Protein Expression and Purification. 2019.
4. TGF3L fusion enhances the antitumor activity of TRAIL by promoting assembly into polymers. Yan Wang, Qiong Lei, Zheng Yan, Cangjie Shen, Nan Wang. Biochem Pharmacol.2018.
5. AUT凝胶电泳在牛胰核糖核酸酶折叠研究中的应用. 邓丽刚，冯崔香，王楠. 现代生物医学进展.2018.
6. Insulin Chains as Efficient Fusion Tags for Prokaryotic Expression of Short Peptides. Ligang Deng.Xiaoying Xue.Cangjie Shen.Xiaohan Song.Chunyang Wang.Nan Wang. Protein Expression and Purification.2017.
7. Ubiquitin-like prokaryotic MoaD as a fusion tag for expression of heterologous proteins in Escherichia coli. Sujuan Yuan, Xin Wang, Jian Xu, Zheng Yan, Nan Wang. BMC Biotechnology. 2014.
8. Conjugation with Cellular Proteins through Disulfide Suggests ThiS as a Possible Prokaryotic Post-translational Modifier. XU Jian, LIU Li-Li, YAN Zheng, WANG Nan.中国生物化学与分子生物学报. 2014.
9. 精氨酸对牛胰核糖核酸酶氧化复性的时相性抑制作用.冯崔香，邓丽刚，闫征，杜国华，王楠.生命科学研究. 2014.
10. Prokaryotic Ubiquitin-Like ThiS Fusion Enhances the Heterologous Protein Overexpression and Aggregation in Escherichia coli. Yuan S, Xu J, Ge Y, Yan Z, Du G, Wang N. PLoS One. 2013.
11. 小鼠核糖核酸酶抑制剂的高效可溶性表达与氧化抗性鉴定. 葛莹，孙婧慧，闫征，王楠.中国生物工程杂志.2010.
12. SAHA and curcumin combinations co-enhance histone acetylation in human cancer cells but operate antagonistically in exerting cytotoxic effects. Jin-Yan Zhao, Na Lu, Zheng Yan, Nan Wang. J Asian Nat Prod Res.2010.
13. 三种药物相互作用数学模型分析SAHA与三氧化二砷联合用药的细胞毒作用. 芦娜，刘振佳，闫征，王楠.药学学报.2010.
14. Antitumor effects of a novel sulfur-containing hydroxamate HDAC inhibitor H40. Long, Juan; Zhao, Jinyan; Yan, Zheng; Liu, Ziliang; Wang, Nan. Int J Cancer.2009.
15. 一种简便可靠的组蛋白乙酰转移酶(HAT)抑制剂荧光检测方法. 赵晋燕，闫征，刘子良，王楠.生物化学与生物物理进展.2008.
16. 组蛋白去乙酰酶抑制剂联合应用治疗肿瘤的研究进展. 龙娟，王楠. 中国新药与临床杂志.2007.
17. Delayed-late activation of a myeloid defensin minimal promoter by retinoids and inflammatory mediators. N Wang, Q Su, S Boeckh-Herwig, M Yaneva, P Tempst. Leukemia Research.2004.
18. 组蛋白去乙酰酶抑制剂的药理学研究进展. 王楠，闫征，刘娜. 中国新药杂志.2004.
19. Synthesis and biological evaluation of pyranocarbazole derivatives as Anti-tumor agents. Ke Liu, Yingda Zang, Cangjie Shen, Chuangjun Li, Jie Ma, Jingzhi Yang, Xingyan Sun, Xinyi Chen, Nan Wang, Dongming Zhang. Bioorg Med Chem Lett.2021.
20. Cytotoxic 9,19-cycloartane Triterpenoids from the Roots of Actaea dahurica. Xu-Yan Wang, Chuang-Jun Li, Jie Ma, Chuan Li, Ji-Wu Huang, Nan Wang, Cang-Jie Shen, Dong-Ming Zhang. Fitoterapia. 2019.
21. Cytotoxic 9,19-cycloartane type triterpenoid glycosides from the roots of Actaea dahurica. Xu-Yan Wang, Chuang-Jun Li, Jie Ma, Chuan Li, Fang-You Chen, Nan Wang, Cang-Jie Shen, Dong-Ming Zhang. Phytochemistry. 2019.
22. Simplified aminocoumarin analogues as anticancer agents：Amino isosteric replacement in the noviose moiety resulted in substantial enhancement of antiproliferative activity. Ting Zhang, Zheng Yan, Yun-Feng Li, Nan Wang. 中国化学快报. 2013.
23. Synthesis and cytotoxicity of 3-aryl acrylic amide derivatives of the simplified saframycin-ecteinascidin skeleton prepared from l-dopa. Guo J, Dong W, Liu W, Yan Z, Wang N, Liu Z. Eur J Med Chem. 2013.
24. Synthesis and cytotoxicity of dinuclear platinum(Ⅱ) complexes of (1S, 3S)-1, 2, 3, 4-tetrahydroisoquinolines. Geng Xu, Ju Guo, Zheng Yan, Nan Wang, Zhan-Zhu Liu. 中国化学快报. 2013.
25. Asymmetric synthesis and cytotoxicity of (-)-saframycin A analogues. Dong W, Liu W, Yan Z, Liao X, Guan B, Wang N, Liu Z. Eur J Med Chem. 2012.
26. Synthesis and cytotoxicity of (-)-renieramycin G analogs. Wei Liu, Wenfang Dong, Xiangwei Liao, Zheng Yan, Baohe Guan, Nan Wang, Zhanzhu Liu. Bioorganic & medicinal chemistry letters. 2011.
27. Synthesis of 5(6)-dihydro-OSW-1 analogs bearing three kinds of disaccharides linking at 15-hydroxy and their antitumor activities. Yuyao Guan, Dan Zheng, Liang Zhou, Haixing Wang, Zheng Yan, Nan Wang, Hong Chang, Pingping She, Pingsheng Lei. Bioorganic & medicinal chemistry letters. 2011.
28. Synthesis and cytotoxicity of cis-dichloroplatinum (II) complexes of (1S,3S)-1,2,3,4-tetrahydroisoquinolines. Geng Xu, Zheng Yan, Nan Wang, Zhanzhu Liu. European Journal of Medicinal Chemistry. 2011.
29. Chemical conjugation of muramyl dipeptide and paclitaxel to explore the combination of immunotherapy and chemotherapy for cancer. Xuqin Li, Junli Yu, Song Xu, Nan Wang, Hongzhen Yang, Zheng Yan, Guifang Cheng, gang Liu. Glycoconj J 2008.
30. Improving Penetration in Tumors With Nanoassemblies of Phospholipids and Doxorubicin. Ning Tang, Gangjun Du, Nan Wang, Chunchun Liu, Haiying Hang, Wei Liang. J Natl Cancer Inst. 2007.
31. PU.1 and a TTTAAA Element in the Myeloid Defensin-1 Promoter Create an Operational TATA Box That Can Impose Cell Specificity onto TFIID Function. Yaneva M, Kippenberger S, Wang N, Su Q, McGarvey M, Nazarian A, Lacomis L, Erdjument-Bromage H, Tempst P. J Immunol. 2006.

1.一种新型TRAIL融合蛋白.中国医学科学院药物研究所. 2020年7月10日.